The third milestone under the collaboration is expected to enable both the firms to rapidly pursue a development candidate.
As a part of the partnership, Jubilant delivers preclinical development candidates and has an option to participate in clinical development.
Endo owns the development and commercial rights to the successful outcomes.
However, Jubilant derives research funding, development milestones and sales royalties on successful commercialization.